Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, has announced a business update conference call and webcast scheduled for August 12, 2024, at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, has announced a business update conference call and webcast scheduled for August 12, 2024, at 8:30 AM ET. The event will feature:
- A business update and overview of operations by CEO Lishan Aklog, M.D.
- Discussion of the company's growth strategy
- Presentation of Q2 2024 financial results by CFO Dennis McGrath
Interested parties can access the webcast via the investor relations section of luciddx.com. For telephone access, U.S. callers should dial 1-800-836-8184, while international listeners should use 1-646-357-8785. The conference call name is "Lucid Diagnostics Business Update". A 30-day replay will be available on the company's website after the call.
Details
News Market Reaction – LUCD
The recorded move for LUCD in the trading session of this news was -3.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast at 8:30AM Eastern Time
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-august-12-2024-302207802.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.